Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labcorp HoldingsLTS:0JSY +3.85%79 3-Year EBITDA Growth Rate is 4.00% as of Mar. 2026, which is 47% below its 10-year median of 7.50. GuruFocus rates LTS:0JSY with a GF Score™ of 79/100 and a GF Value™ of $270.56 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 166 Medical Diagnostics & Research companies, Labcorp Holdings ranks worse than 57.23% on this metric.
During the past 12 months, Labcorp Holdings's average EBITDA Per Share Growth Rate was 15.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 4.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -9.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 3.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Labcorp Holdings was 157.10% per year. The lowest was -57.00% per year. And the median was 7.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Labcorp Holdings 3-Year EBITDA Growth Rate Related Terms
LTS:0JSY vs DGX, MTD, GH: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Labcorp Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labcorp Holdings 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 4.00% mean?
Labcorp Holdings (LTS:0JSY) has a 3-Year EBITDA Growth Rate of 4.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Labcorp Holdings and its competitors. This is 47% below median its historical median of 7.50. According to the industry distribution chart, Labcorp Holdings ranks #95 out of 166 companies in the Medical Diagnostics & Research industry, placing it in the top 57.2%.
Is Labcorp Holdings' 3-Year EBITDA Growth Rate too high?
Labcorp Holdings' current 3-Year EBITDA Growth Rate of 4.00% is 47% below median its 10-year median of 7.50. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 10.80. Labcorp Holdings' value of 4.00% is 63% below this industry median. Based on the distribution chart, Labcorp Holdings ranks #95 out of 166 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Labcorp Holdings has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' 3-Year EBITDA Growth Rate compare to DGX and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Labcorp Holdings ranks #95 out of 166 companies for 3-Year EBITDA Growth Rate. This places Labcorp Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.80. Labcorp Holdings' value of 4.00% is 63% below this benchmark. While the company's 10-year median is 7.50 vs. the industry median of 10.80, Labcorp Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.80, based on 166 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labcorp Holdings's current 3-Year EBITDA Growth Rate of 4.00% is 63% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Labcorp Holdings and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labcorp Holdings's current 3-Year EBITDA Growth Rate is 4.00%, which is 47% below median its own 10-year median of 7.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (LTS:0JSY) is currently considered Modestly Overvalued. The stock's GF Value™ is $270.56, compared to a current price of $311.60 — trading 15.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 4.00%, which is 47% below median its 10-year median of 7.50 and 63% below the Medical Diagnostics & Research industry median of 10.80. Labcorp Holdings' overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Labcorp Holdings (LTS:0JSY), the current 3-Year EBITDA Growth Rate is 4.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labcorp Holdings (LTS:0JSY) Overvalued in 2026?
Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued.
The current stock price of $311.60 is trading 15.2% above its estimated GF Value™ of $270.56.
GuruFocus considers Labcorp Holdings to be Modestly Overvalued.
Key valuation signals for LTS:0JSY:
3-Year EBITDA Growth Rate: 4.00% (47% below median its 10-year median of 7.50)
GF Value™: $270.56 vs. price of $311.60 (15.2% above fair value)
Industry Position: 63% below the Medical Diagnostics & Research median (#95 of 166)
No single metric tells the full story. See the LTS:0JSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
79GF Score
Get the complete analysis for LTS:0JSY
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JSY has been successfully added to your 
